John D. Mendlein
Overview
John D. Mendlein received an average of $3M in total compensation, including $474K in salary, at aTYR PHARMA from 2014 to 2017.
Source: SEC filings on April 3, 2018, March 30, 2017, and April 12, 2016.
Related executives
We found nine more executives who work or worked at aTYR PHARMA.
Sanjay Shukla
aTYR PHARMA
Chief Executive Officer
Jill Broadfoot
aTYR PHARMA
Chief Financial Officer
Nancy Denyes
aTYR PHARMA
General Counsel
Ashraf Amanullah
aTYR PHARMA
Former Senior Vice President, Biologics, Development and Manufacturing
David King
aTYR PHARMA
Chief Scientific Officer
Sanuj Ravindran
aTYR PHARMA
Former Chief Business Officer
Kelly Blackburn
aTYR PHARMA
Vice President, Clinical Affairs
David Weiner
aTYR PHARMA